e-learning
resources
Milan 2017
Tuesday, 12.09.2017
IPF: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Japanese guideline for the treatment of idiopathic pulmonary fibrosis 2017
S. Homma (Tokyo, Japan)
Source:
International Congress 2017 – IPF: from the bench to the bedside
Session:
IPF: from the bench to the bedside
Session type:
Thematic Poster
Number:
3806
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Homma (Tokyo, Japan). Japanese guideline for the treatment of idiopathic pulmonary fibrosis 2017. 3806
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines
Source: Eur Respir Rev 2014; 23:193-214
Year: 2014
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice
Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease
Year: 2009
Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP)
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
Source: Eur Respir J 2015; 46: 186-196
Year: 2015
Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP)
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Registry of idiopathic pulmonary fibrosis patients
Source: International Congress 2016 – Russia Session
Year: 2016
The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF
Source: Eur Respir J 2015; 46: 883-886
Year: 2015
Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Central European idiopathic pulmonary fibrosis (IPF) patients survey
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
Source: Eur Respir J, 55 (4) 1901760; 10.1183/13993003.01760-2019
Year: 2020
Evidence-based treatment strategies in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 163-168
Year: 2013
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept